RGX-202: AFFINITY DUCHENNE Pivotal Trial and Interim Functional Data 

Please join CureDuchenne and REGENXBIO on Tuesday, December 3rd at 2 p.m. E.T. for a community webinar, “RGX-202: AFFINITY DUCHENNE Pivotal Trial and Interim Functional Data.” REGENXBIO will provide an update on its AFFINITY DUCHENNE program of RGX-202, a next-generation micro dystrophin gene therapy. REGENXBIO’s Dr. Naz Dastgir will discuss the company’s pivotal trial plans and share interim clinical data, including the first functional data for RGX-202. 

DATE: Tuesday, December 3, 2024
TIME: 11:00 AM – 12:00 PM Pacific Time  
REGISTER HERE

SPEAKER:
Jahannaz Dastgir, DO
Senior Director, Clinical Development Lead
REGENXBIO 

Jahannaz Dastgir, DO is a pediatric neuromuscular specialist and the clinical development lead of the RGX-202 program at REGENXBIO. This program focuses on AAV8 gene therapy for Duchenne Muscular Dystrophy.